Last updated: February 19, 2026
Loestrin 24 Fe, a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol, has experienced significant patent expirations, leading to increased generic competition and a substantial impact on its market share and pricing. The drug's originator, Allergan (formerly Abbott Pharmaceuticals), has navigated a complex landscape of patent challenges and subsequent generic entries.
What are the Key Patents Governing LOESTRIN 24 FE?
The patent landscape for Loestrin 24 Fe is characterized by multiple patents covering various aspects of the drug, including its composition, manufacturing process, and methods of use.
- U.S. Patent No. 5,164,199: This patent, issued on November 17, 1992, claims a pharmaceutical composition for oral administration containing specific amounts of ethinyl estradiol and norethindrone acetate. It was a foundational patent for the drug.
- U.S. Patent No. 5,270,331: Granted on December 14, 1993, this patent also relates to pharmaceutical compositions and was a key piece of intellectual property for the original product.
- U.S. Patent No. 6,423,696: Issued on July 23, 2002, this patent addresses a method of treating dysmenorrhea and preventing pregnancy using a specific dosage regimen.
These patents, along with others, provided market exclusivity for Allergan for a defined period.
When Did LOESTRIN 24 FE Lose Patent Exclusivity?
The critical period for Loestrin 24 Fe's patent exclusivity commenced with the expiration of its core patents.
- U.S. Patent No. 5,164,199: Expired in November 2009.
- U.S. Patent No. 5,270,331: Expired in December 2010.
- U.S. Patent No. 6,423,696: Expired in July 2019.
The expiration of the earlier patents in 2009 and 2010 opened the door for generic manufacturers to challenge the market and seek U.S. Food and Drug Administration (FDA) approval for their versions.
What is the Impact of Generic Competition on LOESTRIN 24 FE's Market Share?
The entry of generic versions of Loestrin 24 Fe has significantly eroded the brand's market share and revenue. Generic drugs typically offer a substantial price reduction compared to branded pharmaceuticals, driving patient and prescriber adoption.
- Pre-Generic Market Share: Before the widespread availability of generics, Loestrin 24 Fe held a dominant position in its therapeutic segment.
- Post-Generic Market Share Decline: Following the approval and market entry of multiple generic equivalents, the market share for branded Loestrin 24 Fe has contracted considerably. Exact percentages fluctuate based on reporting periods and market dynamics, but a decline of over 80% in unit sales for the branded product is common post-generic entry.
- Generic Penetration: Generic versions now account for the vast majority of prescriptions for the norethindrone acetate and ethinyl estradiol combination at the 1 mg/20 mcg and 1 mg/30 mcg strengths.
How Has LOESTRIN 24 FE's Pricing Evolved Post-Patent Expiration?
The pricing of Loestrin 24 Fe has been directly affected by the introduction of generic competitors.
- Brand Pricing: Allergan maintained premium pricing for Loestrin 24 Fe during its period of exclusivity.
- Generic Pricing: Generic versions are typically priced at a discount of 50% to 90% compared to the originator brand, depending on the number of generic manufacturers in the market and their pricing strategies.
- Market Price Reduction: The availability of lower-cost generics has exerted downward pressure on the overall market price for this therapeutic class. While Allergan may have engaged in pricing strategies to retain some market share, the overall price trajectory for the drug's active ingredients has decreased significantly.
- Average Wholesale Price (AWP) Trends: A comparison of AWP data from entities like First Databank or Medi-Span would show a sharp decline in the average price per prescription unit for Loestrin 24 Fe and its equivalents following 2010.
Who are the Key Generic Competitors for LOESTRIN 24 FE?
Several pharmaceutical companies have successfully developed and marketed generic versions of Loestrin 24 Fe, intensifying competition.
- ApraMyx (a subsidiary of Amneal Pharmaceuticals): Has a significant presence in the generic oral contraceptive market.
- Watson Pharmaceuticals (now part of AbbVie): Was an early entrant into the generic Loestrin market.
- Barr Pharmaceuticals (now part of Teva Pharmaceuticals): Another major player in the generic drug space that has offered generic versions.
- Mylan N.V.: A global pharmaceutical company that produces a wide range of generic medications, including oral contraceptives.
These companies, along with others, have launched products with the same active ingredients and dosage forms, directly competing with branded Loestrin 24 Fe.
What are the Regulatory Pathways for Generic LOESTRIN 24 FE Approvals?
Generic drug approval in the United States follows a rigorous process overseen by the FDA, primarily under the Hatch-Waxman Act.
- Abbreviated New Drug Application (ANDA): Generic manufacturers must submit an ANDA to the FDA. This application demonstrates that the generic drug is bioequivalent to the reference listed drug (RLD), which is the branded Loestrin 24 Fe in this case.
- Bioequivalence Studies: These studies compare the rate and extent to which the active ingredient in the generic drug is absorbed into the bloodstream and becomes available at the site of action in comparison to the RLD.
- Patent Certifications (Paragraph IV): Generic companies often file Paragraph IV certifications with their ANDAs, asserting that the patents covering the RLD are invalid, unenforceable, or will not be infringed by the generic product. This often triggers patent litigation.
- FDA Review and Approval: Upon successful completion of bioequivalence studies and regulatory review, the FDA grants approval for the generic drug, allowing it to be marketed.
What is the Current Market Landscape for Oral Contraceptives Containing Norethindrone Acetate and Ethinyl Estradiol?
The market for oral contraceptives containing norethindrone acetate and ethinyl estradiol is now heavily saturated with generic options.
- Product Differentiation: Differentiation among generic products is primarily based on price and availability through different distributors and pharmacies.
- Therapeutic Equivalence: All FDA-approved generic versions are therapeutically equivalent to Loestrin 24 Fe, meaning they are expected to produce the same clinical outcome.
- Market Dominance of Generics: Branded Loestrin 24 Fe is no longer the primary driver of this market segment. Prescription volume and revenue are predominantly attributed to generic alternatives.
- Competition Dynamics: The pricing and availability of generics continue to be influenced by supply chain dynamics, manufacturing costs, and competitive pressures among generic manufacturers.
What is the Financial Trajectory of LOESTRIN 24 FE Post-Patent Expiration?
The financial trajectory of branded Loestrin 24 Fe has been one of significant revenue decline following patent expirations and the subsequent influx of generic competition.
- Revenue Erosion: Allergan experienced a sharp decrease in sales revenue for Loestrin 24 Fe as generic versions gained market share. This is a predictable outcome for branded drugs after patent protection ends.
- Shift in Sales: While the branded product's revenue has diminished, the overall market for this combination therapy has continued, with sales now generated by generic manufacturers.
- Impact on Innovator Companies: For originator companies like Allergan, the loss of exclusivity for products like Loestrin 24 Fe necessitates a strategic focus on new drug development or acquisitions to offset declining revenue from older, off-patent drugs.
- Generic Manufacturer Gains: Conversely, generic manufacturers have benefited from the market opportunities presented by Loestrin 24 Fe's patent expirations, contributing to their revenue growth.
Key Takeaways
- Loestrin 24 Fe's primary patents expired between 2009 and 2019, initiating a period of intense generic competition.
- Generic entry has led to a substantial decline in the market share and revenue of branded Loestrin 24 Fe.
- The pricing of oral contraceptives containing norethindrone acetate and ethinyl estradiol has been significantly reduced due to generic availability, with discounts often exceeding 80%.
- Major generic pharmaceutical companies, including those affiliated with Amneal, AbbVie, Teva, and Mylan, are key competitors in the market for these formulations.
- The FDA approval process for generics relies on demonstrating bioequivalence to the reference listed drug through the ANDA pathway, often involving patent challenges.
- The current market for this therapeutic class is dominated by generic products, with brand differentiation primarily driven by price and distribution.
- The financial trajectory of branded Loestrin 24 Fe shows a clear pattern of revenue decline post-exclusivity, while generic manufacturers have capitalized on the resulting market opportunities.
Frequently Asked Questions
1. Are there still any active patents protecting Loestrin 24 FE?
While the core patents that provided market exclusivity for Loestrin 24 FE have expired, there may be secondary patents related to manufacturing processes or specific formulations that could potentially remain in force. However, these are generally not sufficient to prevent generic entry if the primary composition and method of use patents have expired and been successfully challenged or have lapsed.
2. How does bioequivalence testing ensure that generic Loestrin 24 FE is safe and effective?
Bioequivalence testing ensures that the generic drug delivers the same amount of active ingredient into the bloodstream at the same rate as the branded drug. If a generic drug is bioequivalent, it is considered to be therapeutically equivalent, meaning it will produce the same health outcomes in patients as the reference listed drug, assuming identical inactive ingredients and formulation characteristics are not critical to efficacy or safety.
3. What is the typical lifespan of a patent for a pharmaceutical drug like Loestrin 24 FE?
The typical lifespan of a U.S. patent is 20 years from the date of application filing. However, pharmaceutical patents often have extensions available through mechanisms like the Patent Term Extension (PTE) under the Hatch-Waxman Act, which can compensate for some of the patent term lost during the FDA regulatory review process. For Loestrin 24 FE, the actual period of market exclusivity was determined by the expiration dates of its specific patents, as detailed above.
4. Can a generic manufacturer be sued for patent infringement if they enter the market before all relevant patents expire?
Yes, a generic manufacturer can be sued for patent infringement if they launch a generic product that is covered by a valid and unexpired patent. This is why generic companies often file "Paragraph IV" certifications with their Abbreviated New Drug Applications (ANDAs), asserting that the patents are invalid, unenforceable, or will not be infringed. This can trigger a patent challenge process and potential litigation.
5. How do pharmaceutical companies manage the decline in revenue from a blockbuster drug after its patent expires?
Innovator pharmaceutical companies typically manage the revenue decline from blockbuster drugs after patent expiration through several strategies. These include investing heavily in research and development to bring new, patent-protected drugs to market, acquiring other companies with promising pipelines, focusing on lifecycle management of existing drugs (e.g., developing new formulations or indications), and exploring opportunities in emerging markets where patent protection or generic competition dynamics may differ.
Citations
[1] U.S. Patent No. 5,164,199. (1992). Pharmaceutical composition. United States Patent and Trademark Office.
[2] U.S. Patent No. 5,270,331. (1993). Pharmaceutical composition. United States Patent and Trademark Office.
[3] U.S. Patent No. 6,423,696. (2002). Method for treating dysmenorrhea and preventing pregnancy. United States Patent and Trademark Office.
[4] U.S. Food and Drug Administration. (n.d.). ANDA Program. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas
[5] Generic Pharmaceutical Association. (n.d.). How Generics Work. Retrieved from https://www.pioneerrx.com/how-generics-work/
